Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
once-weekly semaglutide 1.0 mg s.c. | increase | glycemic control | subjects with type 2 diabetes | - | superior to exenatide ER 2.0 mg in improving | #1 |
once-weekly semaglutide 1.0 mg s.c. | decrease | body weight | subjects with type 2 diabetes | - | superior to exenatide ER 2.0 mg in reducing | #2 |
once-weekly semaglutide 1.0 mg s.c. | no change | safety profiles | subjects with type 2 diabetes | - | had comparable safety profiles | #3 |
once-weekly semaglutide 1.0 mg s.c. | increase | glycemic control | subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs | - | highly effective for | #4 |
OBJECTIVE: To compare the efficacy and safety of once-weekly semaglutide 1.0 mg s.c. with exenatide extended release (ER) 2.0 mg s.c. in subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS: In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks. The primary end point was change from baseline in HbA RESULTS: Mean HbA CONCLUSIONS: Semaglutide 1.0 mg was superior to exenatide ER 2.0 mg in improving glycemic control and reducing body weight after 56 weeks of treatment; the drugs had comparable safety profiles. These results indicate that semaglutide treatment is highly effective for subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs.